Biofilm Formation and Antibiotic Resistance in Orthopaedic Implant Infections: A Molecular Analysis of icaA, icaD, and mecA Genes in an Indian Cohort
摘要
Orthopaedic implant-related infections (OIRIs) are a major clinical challenge, contributing to increased morbidity, prolonged hospitalisation, and higher healthcare costs. This study investigated the prevalence of biofilm-associated genes (icaA, icaD) in Staphylococcus spp., antimicrobial resistance patterns, and the relationship between implant material, infection rates, and treatment outcomes.
MethodsThis was a cross-sectional study of 200 clinical samples from patients with suspected OIRIs. Pathogens were identified using MALDI-TOF MS, and antimicrobial susceptibility was tested according to CLSI 2023 guidelines. Biofilm formation was assessed by a modified microtiter plate assay, and icaA, icaD, and mecA genes were detected by PCR. Statistical analysis, including chi-square tests and logistic regression, was performed to explore associations between implant material, biofilm genes, and infection risk.
ResultsThe mean patient age was 37.99 ± 18.17 years, with males comprising 74%. Fractures were the leading cause of OIRIs (72.5%), predominantly affecting the lower limb (62.5%). Staphylococcus epidermidis (30.2%) and Escherichia coli (15.1%) were the most frequent isolates, with 98% of infections being monomicrobial. Methicillin resistance was common, with 57% of MRSA and 45% of MRSE producing strong biofilms. The icaD gene was significantly associated with biofilm formation (79% in MRSA, 45% in MRSE), whereas icaA showed no such link. Steel implants had the highest infection rate (41.5%), though analysis indicated surgical and patient factors as primary drivers. MDR Gram-negative bacteria displayed high resistance to cephalosporins and fluoroquinolones, with carbapenems and colistin remaining effective.
ConclusionsOIRIs are strongly influenced by biofilm formation and methicillin resistance. Management should prioritize biofilm-targeted therapies, precision antibiotic use, and implant surface innovations to reduce infection risk and improve outcomes.